About SGN-CD70A

SGN-CD70A is an antibody-drug conjugate targeted to CD70, which is expressed in renal cell carcinoma and hematologic malignancies. SGN-CD70A employs our newest proprietary ADC technology. This technology comprises a potent cell-killing agent called a pyrrolobenzodiazepine (PBD) dimer that works by a different mechanism than auristatins. The PBD dimer is stably linked to an antibody with our site-specific engineered cysteines, resulting in uniform drug-loading of two PBD dimers per antibody. We call this engineered antibody an EC-mAb.


SGN-CD70A is being evaluated in a phase 1 clinical trial for patients with renal cell carcinoma.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave